Navigation Links
ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
Date:4/8/2008

LEUVEN, Belgium, April 9 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on vascular diseases, eye diseases and cancer, announces today that it has completed patient enrolment for its Phase II MITI IV study. The primary purpose of this study is to evaluate the safety and preliminary efficacy of microplasmin when administered intravenously to acute stroke patients between four and twelve hours after the onset of the stroke.

MITI IV (Microplasmin in Treatment of Ischemic stroke - IntraVenous) is a Phase II, multicentre, double-blinded, placebo-controlled, ascending-dose clinical trial evaluating the safety of the intravenous administration of microplasmin in 40 patients with acute ischemic stroke. The trial is investigating three dose regimens of microplasmin (2, 3, and 4 mg/kg total dose) and placebo. The trial is also designed to provide preliminary efficacy data using radiographic assessments and plasma surrogate biomarkers. Clinical outcomes are assessed at seven days and 30 days post-treatment, and at each of these visits neurological assessments are performed.

Microplasmin is a truncated form of the natural human protein plasmin, which plays a key role in dissolving blood clots such as those that cause acute stroke. It is a direct-acting thrombolytic agent that has the potential to restore blood flow efficiently within an extended period after a stroke event and has potentially fewer side-effects than other thrombolytic agents. Currently the only approved pharmacologic treatment of acute ischemic stroke is tPA, an indirect-acting thrombolytic. However tPA must be administered within three hours after the stroke has occurred and has the risk of causing unwanted bleeding events.

Dr. Steve Pakola, Chief Medical Officer of ThromboGenics, commenting on today's announcement said: "I am very pleased that we have completed enrolment in this study. We look forward to the results, which shoul
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ThromboGenics Announces 2007 Full Year Results
2. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
3. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
4. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
5. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
6. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
7. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
8. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
9. Compressus Completes Interoperability Implementation for E-Rad Solutions Teleradiology Customers
10. Core Informatics Completes Successful LIMS Implementation for Progenics Pharmaceuticals
11. Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 2014 The Center for Professional ... technical training across the life sciences industry, has partnered ... (SCDM) to provide the organization's members with discounted classroom ... to the more than 350 sessions across 80 course ... off when registering for a public course ...
(Date:12/22/2014)... 22, 2014  Alternative Energy & Environmental Solutions, ... signed a letter of intent to acquire BioTechPharma ... patented a nanotechnology-based development platform used to create ... rapid on-site collection and testing to identify infectious ... in an immediate, non-invasive and cost-effective manner. ...
(Date:12/22/2014)... The American Journal of ... research, reviews and editorials addressing developments and pathways ... published a provocative article exploring the role of ... potential treatment of prostate cancer. , The ... the possibility that there could be a connection ...
(Date:12/19/2014)... Tigard, OR and Hershey, PA (PRWEB) December 19, ... (OTC Pink: BJCT), a leading developer and manufacturer ... has entered into an agreement with Immunomic Therapeutics, ... Bioject’s Biojector®-2000 needle-free injection device with its LAMP™ ... receives an option for an exclusive Worldwide license ...
Breaking Biology Technology:CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3ALNE Announces Intention To Acquire BioTechPharma 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... Dyadic International, Inc. (Pink Sheets: DYAI) ("Dyadic"), a leading-edge early-stage biotechnology ... long-term growth objectives: , , , ... ) , , , ... Anne E. Whitehead as Executive Director of Strategic Alliances . Ms. ...
... Ansell today announced the launch,of their new GAMMEX(R) Powder-Free glove with ... in, Perth, Australia . , , ... It is the first surgical glove which incorporates a proprietary,antimicrobial coating ... in the event of a breach during,surgery. , ...
... INDIANAPOLIS , May 3 ... to our life sciences strengths.  According to a new ... released today at the BIO International Conference in ... with specialized bioscience employment in three of the four ...
Cached Biology Technology:Dyadic International Strengthens Management Team 2Dyadic International Strengthens Management Team 3Dyadic International Strengthens Management Team 4Dyadic International Strengthens Management Team 5Ansell Launches Worlds's First Antimicrobial Surgical Glove 2Indiana Continues to Make Its Mark as a Leading Life Sciences Center 2Indiana Continues to Make Its Mark as a Leading Life Sciences Center 3Indiana Continues to Make Its Mark as a Leading Life Sciences Center 4Indiana Continues to Make Its Mark as a Leading Life Sciences Center 5Indiana Continues to Make Its Mark as a Leading Life Sciences Center 6
(Date:12/10/2014)... 9, 2014 CIE San Diego has launched ... the connective tissue that enhances care coordination among social ... share client-level information; earned a second $1 million grant ... serving seniors aging in community and; will be recognized ... 11 th 4-6p. CIE San Diego ...
(Date:12/4/2014)... GARDENS, Fla. , Dec. 3, 2014 /PRNewswire/ ... solutions, today announced that its DigitalPersona ® ... fingerprint readers have been deployed throughout First Bank ... , South Carolina and ... in Southern Pines, North Carolina ...
(Date:11/21/2014)... Nov. 20, 2014 Strict laws against distracted ... piloting the North American and European automotive sector towards ... gesture recognition systems that are intuitive and able to ... the industry. New analysis from Frost ... Market in Europe and ...
Breaking Biology News(10 mins):Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
... free of charge for all holders of a valid ... access to the onsite press facilities, including a working ... will also be able to assist you in organising ... can register for free online at: http://www.eular.org/congress_press_registration.cfm ...
... researchers at North Carolina State University have found that ... intestinal birth defects may also inhibit the growth and ... chemical compounds created by NC State chemist Dr. Alex ... particular interest to her research: a compound that induced ...
... Indonesia has promised to become a world leader ... committed to a 26% reduction in greenhouse gas emissions ... 14% would have to come from reducing emissions from ... and other bodies are expected to raise total emission ...
Cached Biology News:Compound useful for studying birth defects may also have anti-tumor properties 2Hotspots of carbon confusion in Indonesia threaten to warm the world more quickly 2Hotspots of carbon confusion in Indonesia threaten to warm the world more quickly 3Hotspots of carbon confusion in Indonesia threaten to warm the world more quickly 4Hotspots of carbon confusion in Indonesia threaten to warm the world more quickly 5
... Immunogen: Partially purified chicken intestinal ... vitamin D receptor (VDR) from human, ... fish tissues. This antibody does ... receptors. MA1-710 detects both the ...
Unique enzyme blend containing Taq and Pwo DNA Polymerase and another thermostable enzyme. The Expand 20 kbPLUS PCR System also includes an optimized reaction buffer, MgCl2 solution, and a human cont...
... DNA Polymerase is ideal for high-fidelity ... applications such as cloning and mutagenesis. ... a proprietary enzyme preparation containing recombinant ... proofreading (3'Cut Site5' exonuclease) activity. ...
... supply is a highly compact, extremely reliable and ... knob and one hi-lo range switch control the ... from 20 to 250 volts. One two-position switch ... voltage to output current. For maximum safety, the ...
Biology Products: